• サイトマップ
• 求人情報
• アクセス
• お問い合わせ

更新日：2011年8月4日

1. 論文
   1. 委員会承認の治療研究

      K Tanaka, Y Iwamoto, et al.:Soft-tissue Sarcomas in the Extremities: Japan Clinical Oncology Group Study JCOG0304. Jpn J Clin Oncol.39(4):271-273,2009.

   2. グループ代表者管理の治療研究

      Y Iwamoto, et al.:Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J.J Orthop Sci. 14(4):397-404,2009.

   3. 附随研究等
      • C Kobayashi, Y Iwamoto, et al.:Aberrant expression of CHFR in malignant peripheral nerve sheath tumors. Mod Pathol. 19(4):524-532, 2006.
      • K Kawaguchi, Y Iwamoto, et al.:DNA hypermethylation status of multiple genes in soft tissue sarcomas. Mod Pathol. 19(1):106-114, 2006.
      • T Saito, K Tanaka, Y Iwamoto, et al.:Nuclearβ-catenin correlates with cyclin D1 expressoin in spindle and pleomorphic sarcomas but not in synovial sarcoma. Hum Pathol. 37(6):689-697, 2006.
      • C Kobayashi, K Tanaka, Iwamoto Y, et al.:Chromosomal aberrations and microsatellite instability of malignant peripheral nerve sheath tumors: a study of 10 tumors from nine patients. Cancer Genet Cytogenet. 165(2):98-105, 2006.
      • G Mitsuyoshi, T Ozaki, et al.:Accurate diagnosis of musculoskeletal lesions by core needle biopsy. J Surg Oncol. 94:21-27, 2006.
      • Y Nakagawa, T Ozaki, et al.:Chromosomal and genetic imbalances in synovial sarcoma detected by conventional and microarray comparative genomic hybridization. J Cancer Res Clin Oncol.132:444-450, 2006.
      • H Doi, T Ozaki, et al.:Magnetic resonance angiography without contrast enhancement medium in bone and soft tissue tumors. Oncol Rep. 15: 681-685, 2006.
      • T Matsubara, A Uchida, et al.:Acridine orange used for photodynamic therapy accumulates in malignant musculoskeletal tumors depending on pH gradient. Anticancer Res. 26:187-194,2006.
      • K Shintani, A Uchida, et al.:Expression of hypoxia-inducible factor (HIF)-1alpha as a biomarker of outcome in soft-tissue sarcomas. Virchows Arch. 449:673-681,2006.
      • S Otsuka, J Toguchida, et al.:A variant of the SYT-SSX2 fusion gene in a case of synovial sarcoma. Cancer Genet Cytogenet. 167(1):82-88,2006.
      • Y Kohno, J Toguchida, et al.:Expression of claudin7 is tightly associated with epithelial structures in synovial sarcomas, and regulated by an Ets family transcription factor, ELF3. J Biol Chem. 281(50): 38941-38950,2006.
      • K Yamauchi, H Tsuchiya, et al.:Development of real-time subcellular dynamic multicolor imaging of cancer-cell trafficking in live mice with a variable-magnification whole-mouse imaging system. Cancer Res 66: 4208-4214, 2006.
      • Y Matsui, H Yoshikawa, et al.:A novel type of EWS-CHOP fusion gene in myxoid liposarcoma. Biochem Biophys Res Commun.. 348(2):437-440, 2006.
      • S Morita, H Yoshikawa, et al.:A phase I/II Trial of a WT1 (Wilms' Tumor Gene) Peptide Vaccine in Patients with Solid Malignancy: Safety Assessment Based on the Phase I Data. Jpn J Clin Oncol. 36(4):231-236, 2006.
      • T Sotobori, H Yoshikawa, et al.:Prognostic significance of wilms tumor gene (WT1) mRNA expression in soft tissue sarcoma. Cancer. 106(10):2233-2240, 2006.
      • T Izumi, Y Iwamoto, et al.:Dysadherin expression as a significant prognostic factor and as a determinant of histologic features in synovial sarcoma: special reference to its inverse relationship with e-cadherin expression. Am J Surg Pathol. 31(1): 85-94,2007.
      • A Sakamoto, Y Iwamoto, et al.:Dedifferentiated liposarcoma with leukocytosis. World J Surg Oncol. 5(1): 131, 2007.
      • S Takenaka, N Naka, N Araki, et al.:Prognostic implication of SYT-SSX fusion type in synovial sarcoma: A multi-institutional retrospective analysis in Japan. Oncol Rep. 19(2): 467-476, 2008.
      • J Nishida, T Morita, et al.:Imaging characteristics of the deep-seated lipomatous tumors: intramuscular lipoma, intermuscular lipoma and lipoma-like liposarcoma. J Orthop Sci. 12(6): 533-541, 2007.
      • A Kawai, H Tsuchiya, et al.:Clear cell sarcoma of tendons and aponeuroses: a study of 75 patients. Cancer, 109(1): 109-116, 2007
      • K Hayashi, H Tsuchiya, et al.:Dual-color imaging of angiogenesis and its inhibition in bone and soft tissue sarcoma. J Surg Res. 140(2): 165-170, 2007.
      • A Takeuchi, H Tsuchiya, et al.:Caffeine-potentiated chemotherapy for patients with high-grade soft tissue sarcoma: long-term clinical outcome. Anticancer Res. 27(5B): 3489-3495, 2007.
      • J Taki, H Tsuchiya, et al.:Prediction of final tumor response to preoperative chemotherapy by Tc-99m MIBI imaging at the middle of chemotherapy in malignant bone and soft tissue tumors: Comparison with Tl-201 imaging. J Orthop Res. 26(3):411-418, 2007.
      • Y Hoki, A Uchida, et al.:iNOS-dependent DNA damage in patients with malignant fibrous histiocytoma in relation to prognosis. Cancer Sci. 98(2): 163-168, 2007.
      • A Matsumine, A Uchida, et al.:Expression of decorin, a small leucine-rich proteoglycan, as a prognostic factor in soft tissue tumors. J Surg Oncol. 96(5): 411-418, 2007.
      • Y Hoki, A Uchida, et al.:8-Nitroguanine as a potential biomarker for progression of malignant fibrous histiocytoma, a model of inflammation-related cancer. Oncol Rep. 18(5): 1165-1169, 2007.
      • S Kimura, T Wada, et al.:Clonal T-cell response against autologous pleomorphic malignant fibrous histiocytoma antigen presented by retrieved HLA-A*0206. J Orthop Res. 26(2): 271-278, 2008.
      • T Ueda, N Araki, et al.:Validation of radiographic response evaluation criteria of preoperative chemotherapy for bone and soft tissue sarcomas: Japanese Orthopaedic Association Committee on Musculoskeletal Tumors Cooperative Study. J Orthop Sci. 13(4): 304-312, 2008.
      • R Nakayama, H Chuman, et al.:Association of a missense single nucleotide polymorphism, Cys1367Arg of the WRN gene, with the risk of bone and soft tissue sarcomas in Japan.　Cancer Sci. 99(2): 333-339, 2008.
      • S Takenaka, Ozaki T, et al.:Prognostic implication of SYT-SSX fusion type in synovial sarcoma: a multi-institutional retrospective analysis in Japan. Oncol Rep. 19(2): 467-476, 2008.
      • K Takeda, T Ozaki, et al.:Photodynamic therapy with ATX-S10.Na(II) inhibits synovial sarcoma cell growth.Clin Orthop Relat Res. 466(7): 1726-1733, 2008.
      • J Taki, H Tsuchiya, et al.:Prediction of final tumor response to preoperative chemotherapy by Tc-99m MIBI imaging at the middle of chemotherapy in malignant bone and soft tissue tumors: Comparison with Tl-201 imaging. J Orthop Res. 26(3): 411-418, 2008.
      • Y Kanazawa, H Tsuchiya, et al.:Down-regulation of plakoglobin in soft tissue sarcoma is associated with a higher risk of pulmonary metastasis. Anticancer Res. 28(2A): 655-664, 2008.
      • K Horiuchi, H Morioka, et al.:Growth suppression and apoptosis induction in synovial sarcoma cell lines by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ). Cancer Lett. 272(2): 336-344, 2008.
      • C Fukukawa, J Toguchida, et al.:Radioimmunotherapy of human synovial sarcoma using a monoclonal antibody against FZD10. Cancer Sci. 99(2): 432-440, 2008.
      • T Ishibe, J Toguchida, et al.:Neuronal differentiation of synovial sarcoma and its therapeutic application. Clin Orthop Relat Res. 466(9): 2147-2155, 2008.
      • K Kohashi, Y Iwamoto, et al.:Infrequent SMARCB1/INI1 gene alteration in epithelioid sarcoma: a useful tool in distinguishing epithelioid sarcoma from malignant rhabdoid tumor.Hum Pathol. 40(3):349-355,2009.
      • Y Oda, Y Iwamoto, et al.:Chemokine receptor CXCR4 expression is correlated with VEGF expression and poor survival in soft-tissue sarcoma.Int J Cancer. 124(8):1852-1859,2009.
      • U Yamaguchi, H Chuman, et al.:Functional genome screen for therapeutic targets of osteosarcoma. Cancer Sci. 100(12):2268-2274,2009.
      • T Tsukahara, T Wada, et al.:Scythe/BAT3 regulates apoptotic cell death induced by papillomavirus binding factor in human osteosarcoma. Cancer Sci. 100(1):47-53,2009.
      • C Fukukawa, J Toguchida, et al.:Activation of the non-canonical Dvl-Rac1-JNK pathway by Frizzled homologue 10 in human synovial sarcoma. Oncogene. 28(8):1110-1120,2009.
      • K Kohashi, Y Iwamoto, et al.: Reduced expression of SMARCB1/INI1 protein in synovial sarcoma. Mod. Pathol. (23): 981-990, 2010.
      • S Takenaka, N Araki, et al.: Downregulation of SS18-SSX1 expression in synovial sarcoma by small interfering RNA enhances the focal adhesion pathway and inhibits anchorage-independent growth in vitro and tumor growth in vivo. Int J Oncol. 36:823-831, 2010.
      • T Kubo, N Araki, et al.: Specificity of fusion genes in adipocytic tumors. Anticancer Res. 30:661-664, 2010.
      • K Numoto, T Ozaki, et al.: Frequent methylation of RASSF1A in synovial sarcoma and the anti-tumor effects of 5-aza-2'-deoxycytidine against synovial sarcoma cell lines. J Cancer Res Clin Oncol. 136: 17-25, 2010.
      • H Sugiura, H Morioka, et al.: Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma. J Orthop Sci. 15(5):654-660, 2010.
      • R Nakayama, H Morioka, et al.: Gene expression profiling of synovial sarcoma: distinct signature of poorly differentiated type. Am J Surg Pathol. 34(11):1599-1607, 2010.
      • T Shimizu, H Morioka, et al.: c-MYC overexpression with loss of Ink4a/Arf transforms bone marrow stromal cells into osteosarcoma accompanied by loss of adipogenesis. Oncogene. 29(42): 5687-5699, 2010.
      • Y Jin, J Toguchida, et al.: Absence of oncogenic mutations of RAS family genes in soft tissue sarcomas of 100 Japanese patients. Anticancer Res. 30(1):245-251, 2010.
      • R Nakayama, J Toguchida, et al.: Gene expression profiling of synovial sarcoma: distinct signature of poorly differentiated type. Am J Surg Pathol. 34(11):1599-1607, 2010.
      • T Matsubara, A Matsumine, et al.: Photodynamic therapy with acridine orange in musculoskeletal sarcomas. J Bone Joint Surg Br. 92:760-762, 2010.
      • R Niimi, A Matsumine, et al.: The expression of hDlg as a biomarker of the outcome in malignant fibrous histiocytomas. Oncol Rep. 23:631-638, 2010.
      • S Iwata, S Tatezaki, et al.: Polycomb group molecule PHC3 regulates polycomb complex composition and prognosis of osteosarcoma, Cancer Sci. 101:1646-1652, 2010.
      • T Morii, K Mochizuki, et al.: Inhibition of Heat Shock Protein 27 Expression Eliminates Drug Resistance of Osteosarcoma to Zoledronic Acid, Anticancer Res. 30: 3565-3572, 2010.
   4. 総説・解説
      • 岩本幸英: 軟部腫瘍診断へのアプローチ 整形外科診療実践ガイド 編集：守屋秀繁、糸満盛憲、内田淳正、他. 文光堂. 363-365, 2006.
      • 田仲和宏、岩本幸英: 骨・軟部腫瘍に対する化学療法. 臨床と研究. 83(5):681-684,2006.
      • 田仲和宏、岩本幸英: 骨軟部腫瘍. 医学と薬学. 55(5):712-718, 2006.
      • 坂本昭夫、岩本幸英: 軟部腫瘍におけるエピジェネティクス異常. 細胞. 38(10), 410-413, 2006.
      • 田仲和宏、岩本幸英: 骨・軟部腫瘍. 整形外科. 57(7):854-858,2006.
      • 尾崎敏文. :骨軟部腫瘍診断と治療における近年の進歩. 岡山医学会雑誌. 117:211-217, 2006.
      • 中馬広一　:悪性軟部腫瘍の化学療法-現状と実践-. 整形外科学大系. 中山書店. 149-157, 2006.
      • 松峯昭彦、内田淳正、他: 軟部肉腫の遺伝子治療. 細胞. 38; 20-23, 2006.
      • 松峯昭彦、内田淳正、他: 軟部腫瘍診断のpitfall. 整形・災害外科. 49;1283-1288, 2006.
      • 横山良平: 平滑筋肉腫. 整形外科診療実践ガイド 守屋秀繁編.文光堂. 380-382, 2006.
      • 川口哲、和田卓郎、塚原智英. :骨軟部腫瘍に対する免疫療法. 関節外科. 25:1102-1103, 2006.
      • 井須和男: 滑膜肉腫.整形外科診療実践ガイド 守屋秀繁編.、文光堂. 379-380, 2006.
      • 岩本幸英: 悪性骨腫瘍・悪性軟部腫瘍. からだの科学. 253: 87-90, 2007.
      • 岩本幸英: 骨・軟部に発生する腫瘍の診断と治療. 綜合臨牀, 56(4): 771-772, 2007.
      • 岩本幸英: 四肢悪性骨軟部腫瘍 今日の診断基準．編集：大田健, 奈良信雄. 南江堂. 802-805, 2007.
      • 播广谷勝三, 岩本幸英.（分担執筆）: 四肢悪性軟部腫瘍．今日の処方　第4版, 編集: 浦部晶夫, 大田健, 鎌谷直之,島田和幸, 菅野健太郎, 武谷雄二. 南江堂. 741-742, 2007.
      • 中馬広一, 中谷文彦: 悪性骨軟部腫瘍に対する術前治療-高い治療成績と機能再建を求めた治療法の確立．医学のあゆみ. 221(4): 297-302, 2007.
      • 吉田行弘: 四肢悪性軟部腫瘍の治療. 日大医学誌. 66(4): 321-327, 2007.
      • 吉川秀樹: 骨軟部腫瘍診断のポイントとピットフォール. 骨・関節・靭帯. 20: 359-367, 2007.
      • 和田卓郎, 松村忠紀 :滑膜肉腫，吉川秀樹編，最新整形外科学大系「骨軟部腫瘍および関連疾患」. 中山書店. 392-396, 2007.
      • 和田卓郎, 川口哲, 山下敏彦, 他 :悪性骨軟部腫瘍に対するペプチドワクチン療法. 整形・災害外科. 50:1559-1564, 2007.
      • 岩本幸英:骨・軟部腫瘍.整形外科. 59(7): 733-739, 2008.
      • 岩本幸英:軟部腫瘍. 小児整形外科の実際. 南山堂. 250-254 ,2008.
      • 松田秀一, 岩本幸英:四肢悪性軟部腫瘍.医学と薬学. 59(2): 151-157, 2008.
      • 上田孝文，吉川秀樹，他:骨・軟部悪性腫瘍に対する集学的治療体系の進歩とその最前線.日本整形外科学会雑誌. 82(4): 255-270, 2008.
      • 中馬広一:骨軟部腫瘍. 癌と化学療法. 35(3): 406, 2008.
      • 森岡秀夫，他:悪性骨・軟部腫瘍に対する化学療法効果判定におけるDWIの有用性. 関節外科. 27: 169-175, 2008.
      • 塚原智英, 和田卓郎，他:ペプチドワクチン療法. 整形外科. 59(11): 1334, 2008.
      • J Toguchida , et al.:Molecular genetics of sarcomas: Applications to diagnoses and therapy. Cancer Sci. 100(9):1573-1580, 2009.
      • 岩本幸英, 他:わが国における骨肉腫に対する術前補助化学療法の多施設共同第Ⅱ相試験.(NECO study: NECO-93J, NECO-95J). 日整会誌. 83(9):623, 2009.
      • N Naka, N Araki, et al.: Synovial sarcoma is a stem cell malignancy. Stem Cells. 28:1119-1131, 2010.
      • 岩本幸英: 悪性骨腫瘍, 整形外科専門医テキスト, 南江堂. 東京. 365-72, 2010.
      • 松本嘉寛, 岩本幸英, 他: 進行骨肉腫例に対するsecond-line chemotherapyと新規薬剤療法の開発−現状と展望 整形外科. 61巻8号: 815-820, 2010.
      • 小田義直、岩本幸英, 他: 生検標本による軟部肉腫の組織型･悪性度判定における病理診断の問題点, 日整会誌. 84:1114-1119, 2010
      • 森岡秀夫,他: 軟部腫瘍の診断と治療,臨床整形外科. 45: 209-213, 2010.
      • 川口哲, 和田卓郎: 骨・軟部肉腫のペプチドワクチン療法, 整形外科. 61:714-719, 2010.
      • 松峯昭彦: 整形外科プライマリ・ケアとEBM−軟部腫瘍診断ガイドライン−, Primary Care Frontier. 6:14-615, 2010.
      • 吉川秀樹: 小児骨腫瘍の診断と治療, 日整会誌. 84:1142-1149, 2010.
      • 蛭田啓之, 松本誠一, 他: 骨肉腫術前化学療法の組織学的効果判定, 整形外科. 61(8):764-768,2010.
      • 大野貴敏: 悪性軟部腫瘍の治療, 臨床整形外科. 第45巻第3号. 235-240, 2010.
2. 主な学会発表
   1. 委員会承認の治療研究

      田仲和宏, 岩本幸英 :ＪＣＯＧ骨軟部腫瘍グループにおける「高悪性度非円形細胞軟部肉腫に対するIFO+ADRによる術前術後補助化学療法の第Ⅱ相臨床試験」.第40回日本整形外科学会骨・軟部腫瘍学術集会.2007年7月.

   2. グループ代表者管理の治療研究

      なし

   3. 附随研究等
      • K Kusuzaki. et al.:Clinical outcome of a novel photodynamic therapy technique using acridine orange for synovial sarcomas. 6th Meeting of Asia Pacific Musculoskeletal Tumor Society. Jan 2006
      • T Ishibe, J Toguchida, et al.: Gene-expression pattern and differentiation potential of synovial sarcoma suggests its cell-of-origin as neural crest-derived cells. The Joint Symposium of the IVR 50th Anniversary Symposium and the 2nd International Symposium of Institutes Network. May 2006.
      • T Wada . :Surgical management for bone and soft tissue sarcoma of the upper extremity. 3rd International Symposium on Hand Surgery and the Advances in Hand Therapy. May, 2006.
      • K Kusuzaki A Uchida, et al.: Clinical Outcome of a Novel Photodynamic Therapy Technique Using Acridine Orange for Synovial Sarcoma. 6th Meeting of Asia Pacific Musculoskeletal Tumor Society. Jan 2006.
      • A Matsumine, A Uchida, et al.: Expression of Decorin, a Small Leucine-Rich Proteoglycan, As a Biomarker of Outcome in Soft Tissue Tumor 6th Meeting of Asia Pacific Musculoskeletal Tumor Society. Jan 2006.
      • F Nakatani, H Chuman, et al. :Surgical management of soft tissue sarcomas of the groin The 12th Annual Connective Tissue Oncology Society. Nov 2006.
      • Y Kohno, J Toguchida, et al.: Expression of claudin7 is tightly associated with epithelial structures in synovial sarcomas, and regulated by a member of ets family transcription factor, ELF3. The 12th Annual Connective Tissue Oncology Society. Nov 2006.
      • A Kawai, H Chuman, et al.:Ifosfamide-etoposide chemotherapy in adult soft tissue sarcomas.The 13th Connective Tissue Oncology Society Annual Meeting. Nov 2007.
      • E Kobayashi, H Chuman, et al. :Malignant Peripheral Nerve Sheath Tumor: An analysis of 29 cases at asingle institution.The14th International Symposium on Limb Salvage. Sep 2007.
      • U Anazawa, H Yabe, et al. :Dedifferentiated liposarcoma of the extremities: A study of 45 patients. The14th International Symposium on Limb Salvage. Sep 2007.
      • Y Morimoto , T Ozaki , et al.:Antitumorgenic Effct of the Combination Therapy with Histone Deacetylase Inhibitor and DNA Methylation Inhibitor in Synovial Sarcoma Cell. An AACR Special Conference in Cancer Research Cancer Epigenetics. May 2008.
      • K Numoto, T Ozaki, et al.: Low Expression of RASSF1A Correlated with Poor Survival in the Patient with Synovial Sarcoma. An AACR Special Conference in Cancer Research Cancer Epigenetics. May 2008.
      • T Wada, et al.:The third vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma. The 14th Annual CTOS Meeting. Nov 2008.
      • R Niimi, A Matsumine, et al.:Expression of SAP97 as a biomarker of outcome in malignant fibrous histiocytomas.The 55th Annual Meeting of the Orthopaedic Research Society. Feb 2009.
      • Y Morimoto, T Ozaki, et al.:Response Evaluation Criteria in Solid Tumor (RECIST) in Soft Tissue Sarcoma of Extremity.The 15th Annual Meeting of Connective Tissue Oncology Society. Nov 2009.
      • Y Okada, Y Iwamoto, et al.: Y-box binding protein-1 regulates cell proliferation and associates with clinical prognosis of osteosarcoma. The Orthopaedic Research Society 2011 Annual Meeting .Jan 2011
      • N Naka: Synovial sarcoma is a stem cell malignancy. The 7th Combined meeting of the Orthopaedic Research Societies. Oct 2010.
      • Y Morimoto, T Ozaki, et al.: SNP in FGFR4 at codon 388 is still correlated with overall survival in high-grade soft tissue sarcoma over five years followup. The Connective Tissue Oncology Society 16th Annual Meeting . Nov 2010.
      • E Kobayashi, H Morioka, et al.:Reduced argininosuccinate synthetase is a predictive biomarker for the development of pulmonary metastasis in patients with osteosarcoma. 8th Asia Pacific Musculoskeletal Tumor Society Meeting. Feb 2010.
      • N Asano, H Morioka, et al.: Myxoid Liposarcoma with extrapulmonary metastatic lesions. The Connective Tissue Oncology Society 16th Annual Meeting. Nov 2010.
      • T Tsukahara, T Wada et al.: Scythe/BAT3 regulates apoptotic cell death induced by the osteosarcoma antigen PBF in human osteosarcoma 16th Annual Meeting of the Connective Tissue Oncology Society. Nov 2010.
      • S Kawaguchi, T Wada, et al.: Clinical and immunologic responses of synovial sarcoma patients treated with SYT-SSX fusion gene-derived peptide vaccines. 16th Annual Meeting of the Connective Tissue Oncology Society. Nov 2010.
      • J Toguchida, et al.: In vivo tumor forming-signature of human osteosarcoma cells revealed by genome-wide expression profiling. 8th International Society for Stem Cell Research. Jun 2010.
      • S Tamaki, J Toguchida, et al.: Genetic and epigenetic regulation of synovial sarcoma-associated molecule, FZD10. The Connective Tissue Oncology Society 16th Annual Meeting. Nov 2010.
      • K Hori, A Matsumine, et al.: Clinical outcome of Mie Osteosarcoma Study Protocol (MOS protocol) in the treatment of osteosarcoma patient. 8th Asia Pacific Musculoskeletal Tumor Society Meeting. Feb 2010.
      • N Hashimoto, H Yoshikawa, et al.: A Phase I/II Study of Immunotherapy Targeting WT1 Peptide in Patients with Advanced/Metastatic Bone and Soft-tissue Sarcomas. The Connective Tissue Oncology Society 16th Annual Meeting. Nov 2010.
      • T Tanizawa, S Matsumoto et al.: Clinical outcome of Synovial Sarcoma cases. 8th Asia Pacific Musculoskeletal Tumor Society Meeting. Feb 2010.
   4. 総説・解説
      • 岩本幸英、田仲和宏、他：軟部肉腫の長期治療成績. 第75回日本整形外科学会学術集会. 2002年5月.
      • 中馬広一：高度悪性非円形細胞肉腫に対する化学療法について. 第75回日本整形外科学会学術総会. 2002年5月.
      • 松本誠一、川口智義、他：成人軟部肉腫に対する術後補助化学療法. 第35回日本整形外科学会・骨軟部腫瘍学術集会. 2002年7月.
      • 中馬広一：悪性軟部腫瘍に対する放射線化学療法の効果について. 第40回日本癌治療学会. 2002年10月.
      • 岩本幸英：骨肉腫の治療指針. 第105回西日本整形・災害外科学会.　2003年6月.
      • 岩本幸英：悪性腫瘍の先端的研究と社会への還元. 第106回西日本整形・災害外科学会.　2003年11月.
      • 田仲和宏、岩本幸英：悪性骨軟部腫瘍の浸潤・転移に関わるシグナル伝達分子. 第19回日本整形外科学会基礎学術集会.　2004年10月.
      • 中馬広一：悪性骨・軟部腫瘍の治療ガイドライン. 第42回日本癌治療学会総会. 2004年10月.
      • 戸口田淳也：遺伝子発現プロファイリングからの滑膜肉腫の分子病理解析. 第93回日本病理学会. 2004年6月.
      • 戸口田淳也、石部達也、長山聡、他：骨軟部腫瘍における分子標的治療の開発. 第63回 日本癌学会学術総会. 2004年9月.
      • Y Iwamoto: Recent advance in the treatment of bone and soft tissue sarcomas. The combined academic conference of 16th Asia-Pacific Orthopaedic Association (APOA) and the 59th Annual meeting of Taiwan Orthopaedic Association (TOA). Nov 2010.
      • 尾﨑敏文：骨・軟部腫瘍におけるこの10 年の進歩と将来への展望. 第115回中部日本整形外科災害外科学会.　2010年10月.
      • 戸口田淳也: 肉腫の分子生物学. 第83回日本整形外科学会学術総会. 2010年5月
      • 戸口田淳也: 癌化と再生の接点としての組織幹細胞. 第69回日本癌学会学術総会.　2010年9月.